CALGARY, Aug. 10, 2016 /PRNewswire/ - Dr.
Brad Thompson, President and CEO of
Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY), will
present at the 36th Annual Canaccord Genuity Growth
Conference in a session on Thursday,
August 11th, 2016 at 11:00
a.m. ET. The conference takes place on August 10th and 11th in
Boston, MA.
A live audio link to the webcast session will be available at:
http://wsw.com/webcast/canaccord23/oncyf.
A link to the presentation will also be available on the
company's website at:
http://www.oncolyticsbiotech.com/investor-centre/presentations/. It
is recommended that listeners log on 10 minutes in advance of a
live presentation to register and download any necessary software.
Links to the audio replays will be accessible following the
presentations on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based
biotechnology company focused on the development of oncolytic
viruses as potential cancer therapeutics. Oncolytics'
clinical program includes a variety of later-stage, randomized
human trials in various indications using REOLYSIN®, its
proprietary formulation of the human reovirus. For further
information about Oncolytics, please visit:
www.oncolyticsbiotech.com.
The session and webcast times are subject to change. This
release and the presentation related thereto contain
forward-looking statements which involve known and unknown risks,
delays, uncertainties and other factors not under the Company's
control and which may cause actual results, performance or
achievements of the Company to be materially different from the
results, performance or expectations implied by these
forward-looking statements. Such risks and uncertainties
include, among others, the efficacy of REOLYSIN as a cancer
treatment, the success and timely completion of clinical studies
and trials, uncertainties related to the research and development
of pharmaceuticals and uncertainties related to the regulatory
process. Investors should consult the Company's quarterly and
annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
the forward-looking statements. Investors are cautioned against
placing undue reliance on forward-looking statements. The Company
does not undertake to update these forward-looking statements,
except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.